Polycomb-mediated repression of EphrinA5 promotes growth and invasion of glioblastoma

Barbara Ricci1 · Thomas O. Millner1 · Nicola Pomella1 · Xinyu Zhang1 · Loredana Guglielmi1 · Sara Badodi1 · Dario Ceric1 · Carolina Gemma2 · Erica Cognolato1 · Ying Zhang3 · Sebastian Brandner3 · Michael R. Barnes4 · Silvia Marino1

Received: 19 March 2019 / Revised: 4 December 2019 / Accepted: 15 January 2020 © The Author(s) 2020. This article is published with open access

Abstract
Glioblastoma (GBM) is the most common and most aggressive intrinsic brain tumour in adults. Integrated transcriptomic and epigenomic analyses of glioblastoma initiating cells (GIC) in a mouse model uncovered a novel epigenetic regulation of EphrinA5. In this model, Bmi1 enhances H3K27me3 at the EphrinA5 locus and reinforces repression of selected target genes in a cellular context-dependent fashion. EphrinA5 mediates Bmi1-dependent proliferation and invasion in vitro and tumour formation in an allograft model. Importantly, we show that this novel Polycomb feed-forward loop is also active in human GIC and we provide pre-clinical evidence of druggability of the EFNA5 signalling pathway in GBM xenografts overexpressing Bmi1.

Introduction
Malignant gliomas are the most common intrinsic brain tumours in adults. They grow highly invasively, cannot be completely resected by surgery, and conventional anticancer treatments have limited efficacy, resulting in a dismal overall prognosis. Dysregulation of epigenetic mechanisms, together with genetic mutations, is an essential driver in the progression of malignant gliomas (reviewed in [1]). Therefore, to identify novel druggable targets, it is essential to elucidate the molecular mechanisms of this epigenetic dysregulation.

Polycomb group proteins (PcG) are chromatin associated proteins that maintain hereditable gene repression through histone modification and chromatin remodelling. At least two distinct PcG complexes have been identified, PRC1 and PRC2 (reviewed in [2]). PRC2 is composed of a catalytic subunit, Ezh2, which binds to Suz12 and EED to catalyse trimethylation of histone H3 at lysine 27 (H3K27me3), a bona fide epigenetic silencing mark. PRC1 depends upon PRC2 for recruitment to PcG target genes and is responsible for mono-ubiquitylation of histone H2A at lysine 119 (H2AK119u), an enzymatic activity dependent on the E3 ubiquitin ligase activity of Ring1B, which is enhanced by Bmi1. This sequence of events induces chromatin compaction and inhibition of transcription elongation (reviewed in [3]), although alternative mechanisms of action have also been described [4].

The role of several PcG genes, during the development of the mammalian central nervous system (CNS) and in the maintenance of postnatal stem cells in the adult brain, has been extensively characterised (reviewed in [5]). Loss of function studies in the mouse have shown that Bmi1 is essential for regulation of cell cycle entry of neural
progenitors and for self-renewal of neural stem cells (NSC) [6–8]. These actions are, at least in part, mediated through transcriptional repression of the ink4a locus, encoding for p16\textsuperscript{ink4a} and p19\textsuperscript{arf} [6], and of the cell cycle inhibitor p21\textsuperscript{waf1/cip1} [9, 10].

Cells with “stem-like” properties have been described in many cancers. These cells are essential for tumour maintenance and they frequently express stem cell genes as well as exhibit a stem-cell-like chromatin structure. Bmi1 is highly expressed in glioblastoma stem/initiating cells (GIC) [11] and microRNAs—miR128 and miR218—have been identified, which specifically block glioma self-renewal through Bmi1-downregulation [12, 13]. In keeping with these data, increased tumour latency and a shift towards glioma of a lower histological grade were observed in an experimental murine glial tumour arising in ink4a/arf deficient mice bred into a Bmi1−/− background [14]. Interestingly, knockdown of Bmi1 in human GIC (hGIC) significantly reduced tumour growth in a xenograft mouse model [15]. The role of Ezh2 in oncogenesis is also well characterised and it has been shown to be multimodal. In gliomagenesis, somatic mutations of histone H3 variant H3F3A have been described in paediatric tumours (DIPGs), leading to depletion of H3K27me3 on canonical H3 because of inhibition of PRC2 activity [16]. EZH2 has also been shown to contribute to the pathogenesis of adult high grade gliomas (HGG) via a non-histone mediated interaction with STAT3. In this case, the trimethylation of STAT3 at K180 by EZH2 was essential for aberrant STAT3 activation in GIC [17], a finding known to be associated with poor survival in patients with GBM [18]. There is likely a complex interplay between BMI1 and EZH2 in GBM and recent evidence shows that strategies that simultaneously target multiple epigenetic regulators may be required to control GBM growth [19].

We have recently demonstrated that conditional overexpression of Bmi1 has a different functional impact on CNS development depending on the differentiation stage of neural precursor cells [20], and that this is mediated by the amount of H3K27me3 at the promoter region of selected target genes in a cell-context-dependent fashion [21]. We have also shown that GIC isolated from a mouse model of HGG [22] show a similar epigenetic regulation of Bmi1 target genes [21]. These data are in keeping with increased H3K27me3 being a general mechanism mediating the functional outcome of elevated Bmi1 expression in both non-neoplastic and neoplastic contexts.

Here we have used a combined genome-wide and target gene-driven approach to comprehensively identify target genes and pathways mediating Bmi1 function specifically in GIC as compared with NSC. The availability of non-neoplastic NSC engineered to overexpress Bmi1 allowed us to mimic the physiological fluctuation of Bmi1 expression during neural differentiation.

Results

Differential redistribution of the H3K27me3 mark in mGIC as compared with NSC

In order to define the cellular pathways deregulated in gliomagenesis in a Bmi1-dependent, H3K27me3-mediated manner, we used a well-established mouse model of gliomagenesis that relies on the loss of PTEN and p53, two of the most common genetic alterations in IDH wild-type glioblastoma (GBM) [23]. The model relies on Adeno-Cre-mediated recombination of floxed alleles, either by intraventricular virus injection or by in vitro treatment of NSC prior to their intracerebral injection [22]. HGG develop with good penetrance in this model and cells with tumour initiating properties (mGIC) can be effectively propagated in culture. Our previous findings have shown overexpression of Bmi1 and increased global levels of H3K27me3 in these cells, as compared with NSC [21].

We performed ChIPSeq for H3K27me3 and RNASeq to investigate the genome-wide correlation between the redistribution of this PRC2 mark and its transcriptional impact in gliomagenesis. To mimic the physiological fluctuation of Bmi1 expression in NSC we compared mGIC to non-neoplastic NSC expressing basal or increased (Bmi1-Over) levels of Bmi1 (Fig. 1a). Two biologically independent NSC cultures, two NSC Bmi1-Over cultures, isolated from NestinCre;STOPFloxBmi1, and two mGIC cultures were used for this study.

Analysis of the ChIPSeq datasets using MACS2 identified unique peaks in the neoplastic (cluster A) and non-neoplastic (cluster B) Bmi1 overexpressing context (Fig. 1b, c). Pathway analysis on the ingenuity pathway analysis (IPA) platform identified axonal guidance signalling, glioblastoma multiforme signalling, role of Wnt/GSK-3β signalling and ephrin A signalling, among others, as enriched in mGIC (Fig. S1A).

Comparisons of the transcriptome of mGIC vs NSC and mGIC vs NSC Bmi1-Over identified 7319 shared differentially expressed genes (Fig. 1d; 91% and 84% of all deregulated genes, respectively), of which 3813 were specifically downregulated in mGIC (Fig. 1e). We chose to validate 13 genes that were enriched in pathways of interest, or highlighted as likely to be important in GBM pathobiology after thorough literature review. Of these genes, 10/13 were confirmed to be reduced specifically in mGIC in biological replicas of NSC, NSC Bmi1-Over and mGIC (Fig. 1g).
To determine the molecular pathways that are transcriptionally regulated by the PRC2-mediated H3K27me3 mark, we integrated the RNASeq and ChIPSeq datasets. This identified a core subset of 231 genes that had acquired the H3K27me3 mark in mGIC but not NSC or NSC Bmi1Over (defined as “unique”), and that also had showing genes uniquely or commonly repressed in the comparisons mGIC vs NSC Bmi1Over and mGIC vs NSC. Proportion of commonly repressed genes in mGIC concomitantly enriched for H3K27me3 (mGIC unique concordant) is shown in blue. g qPCR showing the expression levels of a selection of deregulated genes in mGIC across the three studied genotypes—mGIC, NSC Bmi1Over and NSC. e Venn diagram

Fig. 1 Genome-wide analysis of genes and pathway deregulated in mGIC. a Schematic of the experimental setup (non-neoplastic NSC and NSC Bmi1Over as well as neoplastic mGIC). b Average profile of H3K27me3 across the three studied genotypes—mGIC, NSC Bmi1Over and NSC—within 5 kb of the TSS. Scores associated with significantly called peaks in mGIC are plotted over the genomic regions of the three genotypes, centred at the TSS. c The heatmap for H3K27me3 across the three studied genotypes—mGIC, NSC Bmi1Over and NSC. Scores associated with significantly called peaks in mGIC (top panels, cluster A) and in NSC (bottom panels, cluster B) are plotted over the genomic regions of the three genotypes, centred at the TSS. d The heatmap of relative expression of genes deregulated in mGIC across the three studied genotypes—mGIC, NSC Bmi1Over and NSC. e Venn diagram

This identified a core subset of 231 genes that had acquired the H3K27me3 mark in mGIC but not NSC or NSC Bmi1Over (defined as “unique”), and that also had...
concomitant reduced expression (defined as “concordant”) (Fig. 1f). These 231 genes showed significant overlap with 33 datasets of the NIH Roadmap Epigenomics H3K27me3 ChIPSeq database (http://www.roadmapepigenomics.org/) (Fig. S1B).

To begin to assess the translational value of our findings in human GBM, this core subset of genes was comparatively analysed in a publicly available H3K27me3 ChIPSeq dataset of hGIC [24]. In total, 97/231 genes shared the mark in both mGIC and hGIC (Fig. S1C), and a high overlap was found in the molecular pathways that were enriched in both mouse and human contexts (Fig. 1h).

**Transcriptional regulation is Bmi1-dependent in a proportion of H3K27me3 marked genes**

To assess which of the genes identified in the screening described above were dependent on Bmi1 expression, we silenced Bmi1 in mGIC cultures with shRNA (Fig. 2a) and then assessed the expression levels of the genes previously validated. We found that 2/10 validated genes, EfnA5 and Jph3, were upregulated upon Bmi1 silencing, demonstrating that their regulation is Bmi1-dependent (Fig. 2b). Upregulation of EfnA5 upon Bmi1 silencing was confirmed at the protein level by means of western blot (Fig. S2A).

Our ChIPSeq data showed widespread enrichment for H3K27 trimethylation at the EfnA5 locus in mGIC, as compared with both NSC and NSC Bmi1Over, which was accompanied by reduced expression with RNASeq (Fig. 2c). A similar pattern of H3K27me3 enrichment at the EfnA5 locus (Fig. S2B) and reduced expression (Fig. S2C) was observed when we analysed published data from hGIC [24].

ChIP for H3K27me3, followed by qPCR for EfnA5 in mGIC upon silencing of Bmi1, confirmed that H3K27me3 enrichment was dependent on the expression levels of Bmi1 (Fig. 2d).

These data are in keeping with a Bmi1-mediated regulation of EfnA5 via modulation of the levels of H3K27me3 at its promoter in our GBM mouse model.

**Bmi1 controls H3K27me3 levels at the EfnA5 locus via downregulation of JmjD3 in mGIC**

In order to maintain a cell-type-specific expression pattern, H3K27me3 at specific gene loci is finely regulated by histone methylase and demethylase activity [25, 26]. We have previously demonstrated that NSC overexpressing Bmi1 show reduced expression of the demethylase JmjD3, but no significant changes in expression levels of the methylase Ezh2, suggesting that Bmi1 might control the H3K27me3 repressive mark through the downregulation of JmjD3 [21]. To test the potential contribution of JmjD3 in the regulation of H3K27me3 levels in our model, we performed a proximity ligation assay (PLA) for H3K27me3 on the EfnA5 locus (Figs. S3 and 3a) upon overexpression of JmjD3 vs treatment with an Ezh2 inhibitor (Ezh2i).

We show that increased expression of JmjD3 in mGIC (shScr + JmjD3; Fig. 3b top right panel and Fig. 3c) led to a significantly reduced H3K27me3 at the EfnA5 locus as compared with shScr (Fig. 3b top left panel and Fig. 3c) and shScr treated with Ezh2i (shScr + Ezh2i; Fig. 3b top middle panel and Fig. 3c), confirming that JmjD3 plays a major role in regulating the levels of H3K27me3 at the EfnA5 locus in mGIC. In keeping with this interpretation, cells overexpressing JmjD3 and further treated with Ezh2i (shScr + JmjD3 + Ezh2i; Fig. 3b bottom left panel) did not show any significant additional decrease of the H3K27me3 signal as compared with shScr + JmjD3 only (Fig. 3c). Similar results were observed in both shBmi1 and shBmi1 + Ezh2i cells (Fig. 3b bottom middle and bottom right panels, respectively), showing a decreased level of H3K27me3 upon Bmi1 silencing compared with shScr, but no significant additional change when Ezh2i was added. Off-target effects were also ruled out (Fig. 3d).

We conclude that Bmi1 regulates the levels of H3K27me3 via repression of JmjD3 in mGIC (see Fig. S3B for schematic).

**Bmi1 regulates cell morphology, proliferation and migration/invasion via repression of EfnA5 in mGIC**

We have shown above that EfnA5 is upregulated upon Bmi1 silencing. Therefore, we next set out to assess in vitro the functional role of EfnA5 as a mediator of the Bmi1-dependent phenotype of mGIC. We used pre-clustered recombinant mouse EfnA5 Chimera-Fc (rmEfnA5-Fc) to activate EfnA5 forward signalling [27].

EfnA5 regulates focal adhesion, cell motility and cancer invasion via modulation of the actin cytoskeleton [28, 29], therefore we assessed whether upregulation of EfnA5 upon shBmi1 affected cellular architecture in our model. We evaluated the formation of stress fibres, with phalloidin staining, as a measure of EfnA5-mediated activation of focal adhesion as well as cellular process length with GFAP staining. When we compared rmEfnA5-Fc treated mGIC with shBmi1 mGIC, phalloidin intensity was similar (Fig. 4a), and cellular process length was increased in both conditions. These data support the interpretation that exogenous EfnA5 modifies the cytoskeleton and cell morphology in a similar fashion to Bmi1 knockdown, which leads to an endogenous overexpression of EfnA5.

Next, we assessed whether EfnA5 repression contributed to the previously described [15] Bmi1-mediated regulation of cellular proliferation. mGIC treated with rmEfnA5-Fc showed significantly decreased proliferation, with a similar decrease observed in shBmi1 mGIC (Fig. 4c). Expression of
p16^{INK4A}, p19^{ARF} and p21 was not significantly upregulated in this model (Fig. S2D).

In addition, shBmi1 mGIC showed reduced migration potential (Fig. 4d), in keeping with previous reports [14]. A similar phenotype was also observed when mGIC were treated with rmEfnA5-Fc, raising the possibility that modulation of EfnA5 expression levels may contribute to Bmi1-mediated regulation of cell migration.

To assess whether the upregulation of EfnA5 expression observed upon Bmi1 silencing was responsible for the observed phenotype, we used shRNA to knockdown EfnA5 in shBmi1 mGIC (Fig. S4A; “shEfnA5”, with “shmCherry” as the reporter-matched scrambled control). Interestingly, silencing of EfnA5 in shBmi1 mGIC, neutralised the effect of Bmi1 knockdown on stress fibre formation and cellular process length (Fig. 5a). Importantly, the decreased proliferation rate observed in shBmi1 mGIC, as assessed by live imaging (Figs. 5b and S4B) and neurosphere assay (Figs. S4D and S5A), was also rescued when concomitant silencing of EfnA5 was carried out, a finding supported by the lack of significant impact of Bmi1 silencing on the expression of cell cycle inhibitors in our model (Fig. S2D).
Silencing of EfnA5 in shBmi1 mGIC also rescued the migration defect observed in shBmi1 mGIC (Figs. 5c and S4C). Finally, shBmi1 mGIC showed reduced invasion through a 3D collagen gel, which was also rescued by concomitant shEfnA5 (Fig. S5B).
Repression of EphrinA5 by Bmi1 is essential for glioblastoma development in an allograft model

Given these important roles in proliferation, migration and invasion, we asked whether EphrinA5 might also mediate the impact of Bmi1 on tumourigenesis in vivo. Analytical imaging of NODSCID mice with orthotopically implanted luciferase-tagged GMIC revealed that while 5/9 mice injected with control mGIC developed tumours and silencing of Bmi1 strongly suppressed tumour growth (0/9), concomitant silencing of EphrinA5 and Bmi1 rescued tumour incidence (6/9) (Fig. 6a, b). Histological analysis of the engrafted brains revealed high grade glial tumours composed of cells with enlarged, pleomorphic and occasionally hyperchromatic nuclei, frequent mitoses and areas of necrosis (Figs. 6c and S6A, B). Immunostaining for GFAP, Olig2 and Sox2 confirmed the glial nature of these neo-plasms (Fig. 6c).

These data show that repression of EphrinA5 plays a key role in mediating the tumorigenic role of Bmi1 in vivo.

BMI1 also regulates cell proliferation via repression of EFNA5 in hGIC

To understand whether our findings could be translatable to human GBM, we assessed whether a significant correlation existed between BMI1 and EFNA5 expression in human tumours. We used published RNA microarray, RNASeq and single-cell RNASeq datasets from The Cancer Genome Atlas (TCGA), the National Center for Biotechnology Information Gene Expression Omnibus databases and gbmseq.org [30]. Of the TCGA datasets, we found that the dataset with the highest number of tumour samples (hthgu133a, n = 548) showed a strong and significant inverse correlation between BMI1 and EFNA5 (Fig. S7A), whilst the other three datasets did not (data not shown). Next, we interrogated two independent GBM single-cell RNAseq datasets [30, 31], and confirmed that a significant number of tumour cells displayed a negative association between BMI1 and EFNA5 (Figs. 7a and S7B). Furthermore, we sought to establish whether this negative correlation was found in hGIC specifically by analysing two datasets of primary patient-derived cultured hGIC characterised with RNA microarray (GSE89399 [32]) and RNASeq (GSE89623 [33]). Both of these independent hGIC cohorts displayed a strong and significant negative correlation between BMI1 and EFNA5 (Fig. 7b, c).

Next, we tested whether the functional role for the Bmi1/ EphrinA5 axis observed in mGIC was also present in hGIC in vitro. To this end, the Human Glioblastoma Cell Culture (HGCC.se [34]) resource was interrogated. An inverse correlation between the expression of BMI1 and EFNA5 was again observed, although it did not reach statistical significance (data not shown). Interestingly, these 48 hGIC lines could be clustered into two subgroups on the basis of the expression levels of BMI1 and EFNA5, with a strong and significant negative correlation of BMI1 and EFNA5 being observed in primary lines belonging to the Proneural molecular subtype (n = 9; Fig. 7d).

We selected two of these primary Proneural hGIC lines (U3118 and U3033) to examine the translational potential of the BMI1/EFNA5 pathway. Upon BMI1 knockdown with shRNA, we observed a corresponding increase in EFNA5 levels (Fig. 7e), and a significant decrease in proliferation in both lines (Figs. 7h and S7D). Ephrin downstream signal transduction is activated by a complex process that requires the assembly of higher-order ligand and receptor clusters for signalling initiation [27]. Therefore, pre-clustering of recombinant EphrinA5 protein (as we have used with mGIC above) results in activation of the signalling pathway. However, if recombinant protein is added without prior clustering it blocks the ephrin receptor sites and inhibits ephrin pathway signalling [35]. In both lines, activation of the EFNA5 signalling pathway was observed upon BMI1 knockdown, which was rescued by pathway blockade with recombinant proteins, as confirmed by immunofluorescence staining for phosphorylation of selected Eph receptors (U3118 shown in Fig. 7f). We used recombinant chimera-Fc protein for human EFNA5 as well as two of its receptors, EPHA4 and EPHA5, for this pathway inhibition. We show that the decreased proliferation rate observed in hGIC after BMI1 knockdown was rescued with concomitant inhibition of the EFNA5 signalling pathway in U3118 and U3033 (Figs. 7h and S7D, respectively). These data were supported by EdU staining that showed the same decrease upon BMI1 knockdown and rescue with EFNA5 pathway inhibition (Figs. 7g and S7C).

These data are in keeping with the interpretation that repression of EFNA5 also plays an important role in mediating BMI1 function in hGIC.
Doxazosin effectively targets BMI1\textsuperscript{high}/EFNA5\textsuperscript{low}

hGIC in vitro and in vivo

Next, we set out to test the hypothesis that pharmacologically targeting the EFNA5 pathway is effective against hGIC expressing high BMI1 levels. In cells with high levels of BMI1, EFNA5 is repressed, therefore we identified a drug that mimicked EFNA5 action. Doxazosin is a small molecule agonist for Eph receptors for which EFNA5 acts as a ligand (EphA2 and EphA4) [36], independent of the α1-adrenoceptor.
action for which it is commonly used clinically. Upon treatment of U3118shScr and U3118shBMI1 cells with 5 µM doxazosin, proliferation was significantly more impacted in the U3118shScr than it was in the shBMI1 condition (Fig. 8a). Indeed, there was a significant large decrease in proliferation with doxazosin treatment in the shScr group, whilst there was only a small, non-significant difference in the shBMI1 group after eight days (Fig. 8b). Assessment of EphA2–4 phosphorylation (targets of EFNAs5) in shScr and shBMI1 cells upon exposure to doxazosin confirmed activation of the pathway (Fig. 8c, d). Decreased levels of phosphorylation of ERK1/2, a known downstream effector of EphA2 [36], were also detected in shScr cells that were treated with doxazosin, whilst in shBMI1 cells this was not the case (Fig. 8c, d).

We next wanted to see if the results we had observed with doxazosin in vitro could be translated to an in vivo setting. Firstly, we established that doxazosin could cross the blood–brain barrier (BBB) in mice by assessing the levels of the drug in the serum and brain homogenate by liquid chromatography–mass spectrometry after subcutaneous injections of doxazosin (50 mg/kg). The levels of doxazosin in the serum of NODSCID mice reached a peak of nearly 4000 ng/mL, 1 h after injection, whilst the levels in brain homogenate reached a peak of ~50 ng/mg after 2 h (Fig. S8A), a timeframe comparable to that seen in rats [37]. Only approximately 1% of the doxazosin in the serum was entering the brain after subcutaneous injection of doxazosin. The BBB efflux transporter inhibitor elacridar has been shown to be effective pre-clinically in enhancing brain accumulation upon dual administration with several anti-glioma agents [38]. Although it is not known if doxazosin is excreted by these transporters, prazosin, another commonly used α1-adrenoreceptor antagonist sharing high structural similarity with doxazosin, is known to be excreted by these transporters [39, 40]. Two doses of doxazosin, 50 and 100 mg/kg, were combined with either a vehicle control or 100 mg/kg of elacridar (given by oral gavage 4 h before doxazosin dose), and the levels of doxazosin were significantly greater in brain homogenate when doxazosin was combined with elacridar (Fig. S8B), reaching levels nearly 10 times higher than doxazosin alone, at the higher doxazosin dose. We also found that, in agreement with other studies [36, 41], doxazosin did not have any significant side effects in experimental animals.

We intracranially injected 0.5 × 10^6 U3118shScr and U3118shBMI1 cells into NODSCID mice. U3118 xenografts have a median survival of ~37 weeks [32]. To assess the effect of doxazosin at an early tumour stage, at 16 weeks eight mice...
of each shScr and shBMI1 were assigned to either 100 mg/kg elacridar + vehicle, or 100 mg/kg elacridar + 100 mg/kg doxazosin. Mice were culled after treatment and tumour volume (immunohistochemistry for human vimentin) and proliferation (Ki67 staining) and apoptosis (cleaved caspase3 staining) were assessed. Tumour volume was significantly reduced after doxazosin treatment in the shScr cells, whereas there was no significant reduction in shBMI1 xenografts (Fig. 8e, f). Proliferation was reduced upon drug treatment in shScr group but not in the shBMI1 group (Fig. 8e, g). No evidence of cCASP3 positive cells was found. All tumours showed cells with enlarged, pleomorphic and occasional hyperchromatic nuclei on H&E, whilst all conditions show diffuse staining for GFAP (cytoplasmic) and SOX2 (nuclear), with a smaller fraction positive for OLIG2 (Fig. S8C).

These data provide pre-clinical evidence in GBM xenografts that the EFNA5 agonist, doxazosin, is effective against early stages of GBM derived from GIC with a BMI1high/EFNA5low molecular signature.

Discussion

We show here a novel epigenetic regulation of EFNA5 in a mouse model of GBM. This highlights a novel Polycomb feed-forward loop in gliomagenesis, whereby PRC1 reinforces repression of selected target genes in a cellular context-dependent fashion.

Consistent with the critical roles of P53 and PTEN-PI3K-AKT alterations in GBM pathogenesis, GBM genomic and proteomic profiles from TCGA show significant correlation between higher levels of AKT activation and worse prognosis in patients with P53 mutations [42]. To model these pathway alterations, mGIC isolated from HGG arising from NSC/NPC upon intraventricular Adeno-Cre mediated
recombination of $p53^{F/F}/PTEN^{F/F}$ [22] were used. We demonstrate that repression of EphA5 expression via increased trimethylation of H3K27 is a core mechanism mediating the functional outcome of the high levels of Bmi1 seen in $p53^{-/-}$/PTEN$^{-/-}$ mGIC. We did not observe an impact on ink4a/arf in this model, in keeping with existing literature showing a non-functional ink4a/arf pathway in a $p53$ knockout setting [16, 43].

The ephrin/Eph receptor family comprises eight ligands (Efn: Eph receptor interacting ligand) and 14 type I transmembrane receptor tyrosine kinases (Eph: erythropoietin-producing human hepatocellular receptors), which are
Bmi1 is known to regulate miRNAs, such as miR10a [51] promoting cell migration and invasion [52].

Regulation of EfnA5 that has been shown to repress EphA8 in glioma cells, as a miR-10a-3p target in the miRBase database [47]. Hypermethylation at CpG islands of promoter regions to activate EphA2 expression in the developing mouse brain and Eph receptors have been extensively studied. The possibility that a multi-layered regulatory mechanism is at play at a locus playing a key role in gliomagenesis.

The aberrant retention of H3K27me3 as a common epigenetic mechanism mediating the phenotype of Bmi1 overexpression opens a novel conceptual entry point into the interrogation of the role of Bmi1 in gliomagenesis. We show that repression of JmjD3 significantly contributes to the increased H3K27me3 at selected target genes in a mouse model. JmjD3 is the first demethylase to have been shown to antagonise Polycomb silencing, and is required for early neural commitment [53, 54]. ChIPSeq experiments have shown that it is a direct Bmi1/PRC1 target in various model systems [55, 56]. JmjD3 also plays a critical role in late neurogenesis [57]. JmjD3 is induced during differentiation of hGIC, where it promotes a differentiation-like phenotype via chromatin dependent (ink4a/arf locus activation) and chromatin independent (nuclear p53 protein stabilisation) mechanisms [58]. Moreover, ChIPSeq analysis in embryonic stem cells expressing a GFP-tagged version of JmjD3, revealed that JmjD3 targets are enriched in molecular pathways that are critically involved in gliomagenesis. These include the direct regulation of Mdm2 and Akt2 as well as the regulation of genes such as Stat3 and Rhln2, which are involved in GBM Mesenchymal transformation and as downstream effectors of GBM genomic lesions, respectively [59, 60]. Finally, pharmacological inhibition of JmjD3 has been shown to impair the tumourigenic potential of H3K27M DIPG cells by restoring normal levels of H3K27me3 [61].

Our data delineate a novel PcG feed-forward loop in which Bmi1 enhances its repressive efficacy at specific target genes in mGIC by increasing H3K27me3-mediated gene repression. We show that the modulation of EfnA5 expression via regulation of H3K27me3 levels is mGIC specific, thus raising the possibility that a multi-layered regulatory mechanism is at play at a locus playing a key role in gliomagenesis.

We also report that an inverse correlation of gene expression of BMI1/EFNA5 is found in human GBM and in hGIC, and we provide initial evidence that repression of EFNA5 mediates, at least in part, the role of BMI1 in regulating hGIC proliferation. Existing literature in human cells has shown that EFNA5 acts as a tumour suppressor gene in GBM via negative regulation of EGFR [62], thus providing an interpretative framework for the requirement of an epigenetic regulation of this protein in GBM.

The wealth of suggestive evidence linking perturbations in H3K27 methylation to the development of malignant gliomas indicates that it will be essential to further explore whether and how this epigenetic mark could be a rational target for epigenetic therapy to counteract tumour maintenance in GBM. Moreover, Eph receptor/ephrin signalling...
pathways are a promising area for anticancer therapies with strategies for their therapeutic targeting already developed with some already in clinical trials [63]. Here we show that doxazosin, an EFNA5 mimic, inhibits proliferation of GIC in a BMI1-dependent fashion. We demonstrate that doxazosin inhibits the ERK pathway, as assessed by its decreased phosphorylation. We also show that doxazosin is able to cross the BBB in combination with an efflux.

Fig. 8 Doxazosin effectively targets BMI1high/EFNA5low hGIC in vitro and in vivo. a U3118shScr (black) and U3118shBMI1 (green) cells were both treated with either vehicle control or doxazosin (DOX) 5 µM and counted at selected time points (n = 3). b At day 8, the number of U3118shScr DOX treated cells, as a fraction of U3118shScr vehicle treated cells, was significantly less than the number of U3118shBMI1 DOX treated cells as a fraction of U3118shBMI1 vehicle treated cells (n = 3). Western blot (c) and quantitative analysis (d) showing the levels of EphA2–4, phosphorylated EphA2–4, ERK1/2 and phosphorylated ERK1/2 for the same conditions as in (A) (n = 3). e Histology of representative tumour areas with human Vimentin immunohistochemistry, H&E and Ki67; scale bars are 1 mm for hVIM and 50 µm for H&E and Ki67 (n = 8). f Tumour volume assessed by automated quantification of human vimentin immunohistochemistry. g Tumour proliferation assessed by Ki67 count per high power field (HPF). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; error bars represent SEM.
transporter inhibitor. When GIC were orthotopically xenografted into NODSCID mice, treatment with doxazosin recapitulated the in vitro findings in early stage tumours: tumour size was significantly decreased in the shScr tumours with concomitant decreased proliferation, whilst there was no difference in shBMI1 tumours. Together these results provide pre-clinical evidence that precision targeting of Eph receptor/ephrin signalling [64] could be an effective therapeutic tool in GBM overexpressing BMI1.

Material and methods

Generation of mice and genotyping

Transgenic STOPFloxBmi1 mice were previously generated in our laboratory [21]. Activation of Bmi1 overexpression was obtained in embryos by crossing STOPFloxBmi1 and NestinCre mice to generate double transgenic animals, as previously described [21].

Cultures

Primary NSC cultures were prepared from E16.5 STOPFloxBmi1;NestinCre transgenic and control wild-type embryos. Primary mouse PTENF/+;P53F/+ NSC and mGIC were cultured as adherent cells in Neurobasal and DMEM/F12 media containing N2 and B27 supplements and human recombinant FGF and EGF.

ChIPSeq and RNASeq

RNASeq: after trimming and quality control, reads were aligned to the mm10 mouse genome using STAR. Trimmed mean of M-values normalisation was applied to the dataset and differential expression analysis was performed using the Bioconductor package edgeR in R [65], with a quasi-likelihood F-test and an FDR cut-off of 0.05. GEO Record number: GSE141961.

ChIPSeq: after trimming and quality control, reads were aligned to the mm10 mouse genome using Bowtie v2.3.4 (sourceforge.net/projects/bowtie-bio/files/bowtie2/), allowing up to one mismatch per read and discarding multi-mapped reads. The MACS2 algorithm [66] was used to call H3K27me3 peaks (subroutine callpeak) and perform the differential binding analysis (subroutine bdgdiff). GEO Record number: GSE141961.

Proximity ligation assay

We cloned a 578 bp region spanning chr17:62687621-62688198 for EfnA5 locus into a TOPO TA Cloning vector. One microgram of plasmid DNA was used as template to generate a biotintylated probe. Slides with attached cells were then incubated with probes, followed by ligation and amplification steps. Anti-mCherry antibody was used to detect transfected cells.

In vitro functional assays

Proliferation, wound healing scratch assay and invasion assay for mGIC were imaged with IncuCyte ZOOM/Live-Cell Software (EssenBioScience) or INCell 2200 (GE Healthcare) with Developer Toolbox software (GE Healthcare).

Orthotopic transplantation of GIC into NODSCID mice and bioluminescence imaging (BLI)

Six- to twelve-week-old NODSCID mice were anaesthetised and 5 x 10^5 mGIC were injected into the right cerebral hemisphere with the following coordinates from the bregma suture: 2 mm posterior, 2 mm lateral, 4 mm deep, 10° angle. Tumour formation and growth was assessed by BLI for mGIC xenografts.

In vivo treatment with doxazosin

100 mg/kg of doxazosin was given daily by subcutaneous injection and 100 mg/kg elacridar was given by oral gavage every second or third day, 4 h prior to doxazosin dose. Experimental animals (n = 8 for each group) were treated with elacridar and vehicle control, or elacridar and doxazosin. Mice were culled after treatment and brains removed for histological assessment.

All further methods and additional details are included as supplementary material.

Acknowledgements

This work is funded by grants from the MRC (1365533.studentship to BR), The Brain Tumour Charity (GN-000389 clinical research training fellowship to TM and BTC 8/128 to SB), Barts Charity (project and programme grants to SM) and Brain Tumour Research (Centre of Excellence award to SM); YZ was supported by a PhD Overseas research scholarship, UCL–ORS and UCLH Trustees. This research also forms a part of the research themes contributing to the translational research portfolio of Barts and the London Biomedical Research Centre, which is supported and funded by the National Institute of Health Research. LC–MS measurements of doxazosin were carried out by Dr Roberto Buccafusca, SBCS Mass Spectrometry Facility, QMUL. All xenograft tumour histology was performed by IQPath, UCLH, London.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide the link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev. 2013;13:497–510
2. Entrevan M, Schuettengruber B, Cavalli G. Regulation of genome architecture and function by Polycomb proteins. Trends Cell Biol. 2016;26:511–25.
3. Blackledge NP, Rose NR, Klose RJ. Targeting Polycomb systems to regulate gene expression: modifications to a complex story. Nat Rev Mol Cell Biol. 2015;16:643–9.
4. Gil J, O’Loghlen A. PRC1 complex diversity: where is it taking us? Trends Cell Biol. 2014;24:632–41.
5. Tetsa G. The time of timing: how Polycomb proteins regulate neurogenesis. Bioessays. 2011;33:519–28.
6. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb group gene Bmi-1 regulates cell proliferation and senescence through the Ink4a locus. Nature. 1999;397:164–8.
7. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of neural and leukemic stem cells. Nature. 2003;423:255–60.
8. Voncken JW, Schweizer L, Aagaard L, Sattler L, Jantsch MF, van LM. Chromatin-association of the Polycomb group protein BMI1 is cell cycle-regulated and correlates with its phosphorylation status. J Cell Sci. 1999;112:4627–39.
9. Fasano CA, Dimos JT, Ivanova NB, Lowry N, Lemischka IR, Temple S. shRNA knockdown of Bmi-1 reveals a critical role for p21-Rb pathway in NSC self-renewal during development. Cell Stem Cell. 2007;1:87–99.
10. Subkhankulova T, Zhang X, Leung C, Marino S, Bmi1 directly represses p21Waf1/Cip1 in Shh-induced proliferation of cerebellar granule cell progenitors. Mol Cell Neurosci. 2010;45:151–62.
11. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA. 2003;100:15178–83.
12. Godlewski J, Nowicki MO, Bronisz A, Williams S, Otsuki A, Nuovo G, et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008;68:9125–30.
13. Tu Y, Gao X, Li G, Fu H, Cui D, Liu H, et al. MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res. 2013;73:6046–55.
14. Bruggeman SW, Hulsman D, Tanger E, Buckle T, Blom M, Zevenhoven I, et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell. 2007;12:328–41.
15. Abdouh M, Fachino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci. 2009;29:8884–96.
16. Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med. 2017;23:483–92.
17. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013;23:839–52.
18. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010;463:318–25.
19. Jin X, Kim LJY, Wu Q, Wallace LC, Prager BC, Sanvoranant T, et al. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. Nat Med. 2017;23:1352–61.
20. Yadrigi G, Leinster V, Acquati S, Bhagat H, Shakhova O, Marino S. Conditional activation of Bmi1 expression regulates self-renewal, apoptosis, and differentiation of neural stem/progenitor cells in vitro and in vivo. Stem Cells. 2011;29:700–12.
21. Acquati S, Greco A, Licastro D, Bhagat H, Ceric D, Rossini Z, et al. Epigenetic regulation of survivin by bmi1 is cell type specific during corticogenesis and in gliomas. Stem Cells. 2013;31:190–202.
22. Jacques TS, Swales A, Brzozowski MJ, Henriquez NV, Linehan JM, Mirzadeh Z, et al. Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. EMBO J. 2010;29:222–35.
23. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22:425–37.
24. Rheinbay E, Suva ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013;5:1567–79.
25. Agger K, Cloos PA, Christensen J, Pasini D, Rose S, Rappulljer J, et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature. 2007;449:731–4.
26. Spermann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev. 2006;6:846–56.
27. Himanen JP, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L, et al. Architecture of Eph receptor clusters. Proc Natl Acad Sci USA. 2010;107:10860–5.
28. Wozniak MA, Modzelewksa K, Kwong L, Keely PJ. Focal adhesion regulation of cell behavior. Biochim Biophys Acta. 2011;1808:1692/2004:103–19.
29. Zhong C, Kineh MS, Burridge K. Rho-stimulated contractility contributes to the fibroblast phenotype of Ras-transformed epithelial cells. Mol Biol Cell. 1997;8:3239–49.
30. Darmanis S, Sloan SA, Croote D, Mignardi M, Chernikova S, Samghababi P, et al. Single-cell RNA-Seq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma. Cell Rep. 2017;21:1399–410.
31. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396–1401.
32. Seegerman A, Niklasson M, Haglund C, Bergstrom T, Jarvis M, Xie Y, et al. Clonal variation in drug and radiation response among glioma-initiating cells is linked to proneural–mesenchymal transition. Cell Rep. 2016;17:2994–3009.
33. Pollak J, Rai KG, Funk CC, Arora S, Lee E, Zhu J, et al. Ion channel expression patterns in glioblastoma stem cells with functional and therapeutic implications for malignancy. PloS One. 2017;12:e0172884.
34. Xie Y, Bergstrom T, Jiang Y, Johansson P, Marinescu VD, Lindberg N, et al. The human glioblastoma cell culture resource: validated cell models representing all molecular subtypes. EBio-Medicine. 2015;2:1351–63.
35. Overman JJ, Clarkson AN, Wanner IB, Overman WT, Eckstein I, Maguire JL, et al. A role for ephrin-A5 in axonal sprouting, recovery, and activity-dependent plasticity after stroke. Proc Natl Acad Sci USA. 2012;109:E2230–2239.

36. Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrip G, et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One. 2012;7:e42120.

37. Kaye B, Cussans NJ, Faulkner JK, Stopher DA, Reid JL. The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br J Clin Pharmacol. 1986;21 Suppl 1:195–25S.

38. Lin F, de Gooijer MC, Hanekamp D, Brandsma D, Beijnen JH, Van Tellingen O. Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. CNS Oncol. 2013;2:271–88.

39. Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, et al. New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther. 2007;6:3271–8.

40. Robey RW, Hongo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer. 2003;89:1971–8.

41. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res. 2000;60:4550–5.

42. Hu B, Wang Q, Wang YA, Hua S, Saucé CG, Ong D, et al. Epigenetic activation of WNTsA drives glioblastoma stem cell differentiation and invasive growth. Cell. 2016;167:1281–95 e1218.

43. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NFI. Cancer Cell. 2010;17:98–110.

44. Libsath EM, Falivelli G, Pasquale EB. Eph receptor signaling and ephrins. Cold Spring Harb Perspect Biol. 2013;5:a009159.

45. Gucciardo E, Sugiyama N, Lehti K. Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics. Cell Mol Life Sci. 2014;71:3685–710.

46. Day BW, Stringer BW, Boyd AW. Eph receptors as therapeutic targets in glioblastoma. Br J Cancer. 2014;111:1255–1265.

47. Chen J, Ruley HE. An enhancer element in the EphA2 (Eck) gene sufficient for rhombomere-specific expression is activated by HOXa1 and HOXB1 homeobox proteins. J Biol Chem. 1998;273:24670–5.

48. Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W, et al. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood. 2010;115:2412–9.

49. Yu CH, Xu CF, Li YM. Association of MicroRNA-223 expression with hepatic ischemia/reperfusion injury in mice. Dig Dis Sci. 2009;54:2362–6.

50. Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS. Differential regulation of EphA2 in normal and malignant cells. Am J Pathol. 2003;162:1037–42.

51. Gargiulo G, Cesarini M, Serresi M, de Vries N, Hulsman D, Bruggeman SW, et al. In vivo RNAi screen for BMI1 targets identifies TGF-beta/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis. Cancer Cell. 2013;23:660–76.

52. Yan Y, Wang Q, Yan XL, Zhang Y, Li W, Tang F, et al. miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8. FEBS Lett. 2015;589:756–65.

53. Burgold T, Sprefaco F, De Santa F, Totaro MG, Prosperini E, Natoli G, et al. The histone H3 lysine 27-specific demethylase Jmjd3 is required for neural commitment. PLoS One. 2008;3:e3034.

54. De Santa F, Naran V, Yap ZH, Tusi BK, Burgold T, Austenaa L, et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 2009;28:3341–52.

55. Morey L, Alota L, Cozzuto L, Benitah SA, Di Croce L. RYBP and Cbx7 define specific biological functions of polycomb complexes in mouse embryonic stem cells. Cell Rep. 2013;3:60–9.

56. van den Boom V, Maat H, Guguien M, Rodriguez Lopez A, Sotoca AM, Jaques J, et al. Non-canonical PRC1.1 targets active genes independent of H3K27me3 and is essential for leukemogenesis. Cell Rep. 2016;14:332–46.

57. Burgold T, Voituron N, Caganova M, Tripathi PP, Menuet C, Tusi BK, et al. The H3K27 demethylase JMD3 is required for maintenance of the embryonic respiratory neuronal network, neonatal breathing, and survival. Cell Rep. 2012;2:1244–58.

58. Ene CI, Edwards L, Riddick G, Baysan M, Woolard K, Kotliarova S, et al. Histone demethylase Jumonji D3 (JMD3) as a tumor suppressor by regulating p53 protein nuclear stabilization. PLoS ONE. 2012;7:e51407.

59. Frattini V, Trifonov V, Chan JM, Castano A, Liria M, Abate F, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet. 2013;45:1141–9.

60. Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med. 2014;20:1394–6.

61. Li JJ, Liu DP, Liu GT, Xie D. EphrinA5 acts as a tumor suppressor in glioma by negative regulation of epidermal growth factor receptor. Oncogene. 2009;28:1759–68.

62. Boyd AW, Bartlett PF, Lackmann M. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov. 2014;13:39–62.

63. Ferluga S, Tome CM, Herpai DM, de Vries N, Hulsman D, Bruggeman SW, et al. In vivo RNAi screen for BMI1 targets identifies TGF-beta/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis. Cancer Cell. 2013;23:660–76.

64. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.